The first hub & spoke diagnostic service dedicated to Human Papillomavirus
Ulisse BioMed proposes a specific offer for the detection and genotyping of Human Papillomavirus (HPV) to physicians and professionals in the gynecological sector.
All professionals who collaborate with Ulisse Biomed are guaranteed CE IVD tests with high clinical performance, carried out in an authorized and certified laboratory, completed with an integrated and complete service to support the analysis itself: sample shipment, integrated logistics, digital reporting, dedicated specialist assistance and much more.
Ulisse BioMed guarantees complete process traceability: samples status updates in real time, their arrival at the laboratory and their subsequent analysis and reporting.
The whole system is managed through our dedicated website www.hpvpro.com, that offers integrated and cybersafe database patient management and reports in digital format which are guaranteed within 3 days from samples receival.
This analysis offers detection and complete genotyping of the 14 HPV genotypes with high oncogenic risk, i.e. those that together cause more than 90% of cervical cancers.
one sample, many tests
This additional analysis allows to detect and genotype, on the same biological sample, further 5 other strains considered by the IARC as possible oncogenes, normally not detected by screening tests but still quite common in the population. These strains are dangerous as they are associated with tumors of the uterine cervix and anogenital area.
This analysis offers the detection and additional genotyping of low-risk HPV strains, ie those that together cause more than 95% of anogenital polyps and warts, as well as some tumors always afferent to the anogenital area. The probability of a cancerous evolution of common warts depends on the HPV genotype responsible for the disease; the viral genotypes normally involved (low risk, analyzed with this type of test) have a low degree of association with malignant lesions, while the high-risk strains present a high risk of neoplastic evolution.
This analysis offers the detection and additional genotyping of the most common HPV strains of the anogenital area, offering an extensive analysis that allows information on genotypes with probable high risk of tumor development, and on low-risk genotypes associated with warts.
Low-risk viral genotypes have a low degree of association with malignant lesions, while genotypes with probable high oncogenic risk present a significant risk of pretumor transformation.
Together with HPV PRO 14 HR results, the clinician will have a complete overview of the strain(s) possibly present in the patient and then to evaluate the probability of a neoplastic evolution, whether benign or malignant, depending on any HPV genotype present.
For further informationContact Us